Patient Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 2014
November 11, 2014 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Nov 11, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix's New Chief Operating Officer Dr. James Alexander Addresses Shareholders
October 31, 2014 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Oct 31, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
October 23, 2014 11:51 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Oct 23, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology,...
Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis
October 13, 2014 09:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Oct 13, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology,...
Cellceutix Provides Update to Shareholders
September 24, 2014 12:28 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Sep 24, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology,...
Cellceutix to President Obama: We Have the Tools and Will Rise Up to the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a Serious Threat to Public Health
September 19, 2014 07:15 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Sep 19, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology,...
Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
September 09, 2014 15:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Sep 9, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology,...
Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
September 05, 2014 11:15 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Sep 5, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology,...
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
September 02, 2014 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Sep 2, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology,...
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
August 19, 2014 08:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Aug 19, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology,...